News about "Novartis"

Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria

Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.

Novartis | 19/02/2026 | By News Bureau

Novartis Builds Global Biomedical Research Centre in San Diego

Novartis launches construction of a 466,000-square-foot biomedical research centre in San Diego, set to open in 2029, strengthening global drug discovery and advancing neuroscience, oncology and next-generation therapies.

Novartis | 09/02/2026 | By News Bureau

Patent Expiry Headwinds to Drive Novartis Operating Profit Down in 2026

Swiss pharmaceutical major Novartis has forecast a modest decline in operating profit for 2026, marking its first annual drop in a decade amid the looming impact of key drug patent expiries.

Novartis | 05/02/2026 | By Darshana |  238

Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease

The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.

Novartis | 19/01/2026 | By News Bureau |  120

Novartis, SciNeuro Sign USD 1.7 Billion Licensing Deal to Develop Alzheimer's Therapies

Novartis has entered into an exclusive global licensing and collaboration agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for Alzheimer’s disease, in a deal valued at up to USD 1.7 billion.

Novartis | 13/01/2026 | By Darshana |  259

Novartis to Add Fourth US Radioligand Therapy Plant in Florida

Novartis will expand its US radioligand therapy manufacturing network with a new purpose-built facility in Winter Park, Florida, strengthening patient access across the southeastern US and supporting the company’s broader USD 23 billion investment in advanced manufacturing and oncology innovation.

Novartis | 12/01/2026 | By News Bureau |  140

Sanofi and Novartis Reach Separate Agreements with US Government to Lower Drug Prices and Support Innovation

Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.

Novartis | 22/12/2025 | By News Bureau |  181

Novartis Breaks Ground on Flagship Manufacturing Hub in North Carolina

Novartis has officially begun construction of its flagship manufacturing hub in North Carolina, reinforcing its commitment to end-to-end production of key medicines for US patients. The project, highlighted by FDA Commissioner Marty Makary and Governor Josh Stein, underscores Novartis’ ongoing investment and growth in the US pharmaceutical sector.

Novartis | 15/12/2025 | By News Bureau |  348

Lupin Receives Tentative US FDA Nod for Siponimod Tablets, Generic to Novartis' Mayzent

Lupin has received tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Siponimod Tablets in strengths of 0.25 mg, 1 mg and 2 mg.

Novartis | 05/12/2025 | By Dineshwori |  282

Novartis to cut 550 jobs in Switzerland as it shifts focus to cell therapy and advanced biologics

Novartis announced plans to eliminate 550 jobs in Switzerland by the end of 2027 as part of a strategic shift toward cell therapy, RNA-based medicines, and other advanced biologics. The cuts will primarily affect its Stein facility, where the company is phasing out the production of pills, capsules, and sterile medicine packaging.

Novartis | 27/11/2025 | By Darshana |  313